Drug Development

Company exercises option for rights to blood platelet modification technology

Published in Women's Health Weekly, April 7th, 2005

ZymeQuest, Inc. (ZymeQuest), which discovers, develops and commercializes carbohydrate-modified blood products for use in transfusion medicine, announced that it has exercised its option to license worldwide rights to a new method of treating platelets developed by Brigham and Women's Hospital (BWH).

The new method, designed to enable platelets to be stored under refrigeration, could prolong their shelf life by a week or more. BWH granted the option to ZymeQuest in May 2004.

Research on this platelet modification methodology has been conducted by BWH with scientific support and assistance from ZymeQuest. BWH and ZymeQuest share proprietary rights to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2005-04-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry